Evidence map›Paper›PMID 42028740›Full record

ReviewInternational journal of oncology2026

Research advances in aptamers in the diagnosis and treatment of breast cancer (Review).

Liqiang Chu, Yunfeng Xiao, Xinhua Li, Jiawei Cui, Luyao Ma, Bin Shao, Hongwei Cui

Abstract readReview
In one paragraph

Review in International journal of oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Liqiang Chu *School of Graduate, Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region 010059, P.R. China.
Yunfeng Xiao *School of Pharmacy, Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region 010059, P.R. China.
Xinhua LiSchool of Graduate, Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region 010059, P.R. China.
Jiawei CuiSchool of Graduate, Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region 010059, P.R. China.
Luyao MaSchool of Graduate, Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region 010059, P.R. China.
Bin ShaoDepartment of Scientific Research, Breast Cancer Center, Affiliated Cancer Hospital of Inner Mongolia Medical University/Peking University Cancer Hospital (Inner Mongolia Campus), Hohhot, Inner Mongolia Autonomous Region 010050, P.R. China.
Hongwei CuiDepartment of Scientific Research, Breast Cancer Center, Affiliated Cancer Hospital of Inner Mongolia Medical University/Peking University Cancer Hospital (Inner Mongolia Campus), Hohhot, Inner Mongolia Autonomous Region 010050, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is a malignant disease that threatens human life and health. Among cancer types, breast cancer is one of the most common malignant tumors in women worldwide and ranks among the top cancer types in terms of incidence rate of malignant tumors in Chinese women. Aptamers are a class of DNA or RNA sequences that can bind to specific targets through their three‑dimensional structures, and are screened and obtained via systematic evolution of ligands by exponential enrichment technology. Aptamers have advantages of high affinity and specificity, strong stability, low immunogenicity, a wide range of targets and ease of preparation and purification. As effective molecular targeting tools and drug delivery carriers, aptamers and their conjugates show therapeutic potential in the early diagnosis and treatment of breast cancer. The present article reviewed the properties and screening techniques of aptamers, as well as their applications and research progress in the diagnosis and treatment of breast cancer, with the aim of providing new strategies and directions for the realization of precision medicine for breast cancer via aptamers.

Indexed as

Aptamers, NucleotideBreast NeoplasmsFemaleHumansMolecular Targeted TherapyPrecision MedicineSELEX Aptamer TechniqueAptamers, Nucleotideaptamerbreast cancerdiagnosisprecision medicinetherapy

Identifiers

PMID42028740
PMCPMC13124140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.